Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282107 | 0.86 | MAPK1 (0.61) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL29600721 | 0.83 | HTR3E (0.53) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL307695 | 0.83 | HTR3E (0.53) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL11748612 | 0.82 | MAPK1 (0.53) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL25271568 | 0.82 | MAPT (0.44) | TDP1MAPK1ALDH1A1HPGDKMT2A | |
| SCHEMBL11804851 | 0.81 | MAPK1 (0.56) | TDP1MAPK1CYP3A4KMT2ATRPA1 | |
| SCHEMBL1428432 | 0.81 | TDP1 (0.56) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL11826875 | 0.80 | TDP1 (0.54) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL124245 | 0.80 | CYP3A4 (0.59) | TDP1MAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL29510769 | 0.80 | CYP3A4 (0.59) | TDP1MAPK1ALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-116768764-A | Process for preparing urea derivatives | 安道麦阿甘有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-106008276-A | Synthesis method of phenylurea herbicide or deuteration-labeled phenylurea herbicide | 湖北出入境检验检疫局检验检疫技术中心 | 2016-10-12 | — | — | CN | claimed |
| CN-103614109-A | Polyurethane adhesive for package materials | SUZHOU SIDIKE NEW MAT SCIENCE & TECHNOLOGY CO LTD | 2014-03-05 | — | — | CN | claimed |
| CN-102618205-B | Polyurethane composite adhesive | SUZHOU SIDIKE NEW MATERIAL SCIENCE AND TECHNOLOGY CORP | 2013-10-30 | — | — | CN | claimed |
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| WO-2004096794-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004048319-A1 | NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003087045-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
| EP-0679085-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-11-02 | — | — | EP | disclosed |
| US-5378714-A | Treatment of depression, anxiety, schizophrenia, affinity for 5HT2 receptors | NOVO NORDISK A/S (DK) | 1995-01-03 | — | — | US | disclosed |
| WO-1993010742-A2 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-10 | — | — | WO | disclosed |
| US-3994714-A | N-(3-CHLORO-4-METHOXYPHENYL)-N*,N*-DIMETHYLUREA | SANDOZ LTD. (CH) | 1976-11-30 | — | — | US | disclosed |
| US-3983172-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | TDP1 1868/4885MAPK1 3358/4885ALDH1A1 4150/4885 |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | TDP1 504/4885MAPK1 3672/4885ALDH1A1 1073/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | TDP1 1837/4885MAPK1 2175/4885ALDH1A1 330/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | TDP1 1726/4885MAPK1 1737/4885ALDH1A1 274/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | TDP1 1726/4885MAPK1 1737/4885ALDH1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.